Literature DB >> 11297253

Multiple detection of genetic alterations in tumors and stool.

C Rengucci1, P Maiolo, L Saragoni, W Zoli, D Amadori, D Calistri.   

Abstract

Detection of genetic alterations in exfoliated intestinal cells in stool could represent an alternative, noninvasive tool for the screening of colorectal tumors. To verify this, we analyzed p53 and K-ras mutations and microsatellite instability on 46 cases of colorectal cancer and compared the presence of molecular alterations in tumor tissue and stool samples from individual patients. p53 exons 5-8 and K-ras exons 1-2 were analyzed by denaturing gradient gel electrophoresis. For the microsatellite instability, a set of 5 microsatellite markers (D2S123, D5S346, D17S250, BAT25, and BAT26) was evaluated. In the 18 healthy individuals, no genetic alterations in either tissue or stool were detected. p53 mutations were detected in 17 (37%), K-ras alterations in 15 (33%), and microsatellite instabilities in 5 (11%) of the 46 tumors analyzed. In a side study, we analyzed the correlation in genetic alteration profiles between tumors and macroscopically normal or healthy tissue from the same patient. The presence of at least one molecular alteration in tumor was observed in 31 (67%) of the cases. p53, K-ras mutations, and microsatellite instabilities were detected in stool samples in 18, 40, and 60% of patients with tumors harboring the same alterations. Due to the largely complementary presence of p53 and K-ras mutations in tumors, the use of highly sensitive procedures for stool analysis could offer a means competitive with colonoscopy and the fecal occult blood test.

Entities:  

Mesh:

Year:  2001        PMID: 11297253

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  BRAF, K-ras and BAT26 mutations in colorectal polyps and stool.

Authors:  Ying-Min Jin; Bao-Jie Li; Bo Qu; Ya-Ju Du
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

2.  Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.

Authors:  Carolin Tonus; Gero Neupert; Markus Sellinger
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

3.  Stool DNA and occult blood testing for screen detection of colorectal neoplasia.

Authors:  David A Ahlquist; Daniel J Sargent; Charles L Loprinzi; Theodore R Levin; Douglas K Rex; Dennis J Ahnen; Kandice Knigge; M Peter Lance; Lawrence J Burgart; Stanley R Hamilton; James E Allison; Michael J Lawson; Mary E Devens; Jonathan J Harrington; Shauna L Hillman
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

4.  Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool.

Authors:  Daniele Calistri; Claudia Rengucci; Arturo Lattuneddu; Gianfranco Francioni; Anna Maria Polifemo; Oriana Nanni; Luca Saragoni; Franco Monti; Alberto Ravaioli; Wainer Zoli; Dino Amadori
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

5.  Fecal molecular markers for colorectal cancer screening.

Authors:  Rani Kanthan; Jenna-Lynn Senger; Selliah Chandra Kanthan
Journal:  Gastroenterol Res Pract       Date:  2011-11-17       Impact factor: 2.260

6.  Improved recovery of exfoliated colonocytes from feces using newly developed immunomagnetic beads.

Authors:  Yoshikatsu Koga; Masahiro Yasunaga; Satoshi Katayose; Yoshihiro Moriya; Takayuki Akasu; Shin Fujita; Seiichiro Yamamoto; Hideo Baba; Yasuhiro Matsumura
Journal:  Gastroenterol Res Pract       Date:  2008-12-22       Impact factor: 2.260

7.  Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer.

Authors:  P D Hardt; S Mazurek; M Toepler; P Schlierbach; R G Bretzel; E Eigenbrodt; H U Kloer
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

Review 8.  Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection.

Authors:  Hicham Mansour
Journal:  Front Genet       Date:  2014-08-27       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.